Transcatheter Aortic Valve Replacement: An Update in Bicuspid Aortic Valve Disease

Considering the promising outcomes and FDA approval in low-risk patients, the number of transcatheter aortic valve replacement (TAVR) procedures is expected to increase significantly in the coming years. According to the most recent data presented at the American College of Cardiology (ACC) 2020, bicuspid aortic valve disease (BAV) patients who undergo TAVR procedures had a low risk of death or disabling stroke and high rate of success with a newer self-expanding artificial valve (Evolut supra-annular self-expanding valves, Medtronic). Further, BAV patients reported to have a similar rate of death compared with tricuspid aortic valve disease patients following TAVR using the balloon-expandable valve (Edwards Sapien 3, Edwards Lifesciences).

Improving efficacy and reduction in operator variability is essential to ensure the adoption of TAVR for BAV patients. In particular, the BAV morphologies will remain challenging and require accurate pre- and peri-procedural work up.

This programme has therefore been designed for an audience of cardiologists and surgeons to build their understanding of bicuspid valve disease and classifications, clinical trial data supporting TAVR in low-risk bicuspid patients, implant techniques, and device considerations for bicuspid patients.